Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 (2021) Kayser S, Martinez-Cuadron D, Hanoun M, Stoelzel F, Gil C, Reinhardt HC, Aguiar E, et al. Conference contribution Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia (2021) Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al. Conference contribution Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis (2021) Dreger P, Schubert ML, Holtick U, Subklewe M, Von Bastian T, Ayuk FA, Wagner EM, et al. Conference contribution Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis (2021) Bethge WA, Martus P, Schmitt M, Holtick U, Borchmann P, Subklewe M, Rejeski K, et al. Conference contribution Prognostic Value of Elafin in Acute Graft-Versus-Host Disease (2021) Zewde MG, Morales G, Gandhi I, Ozbek U, Aguayo-Hiraldo P, Ayuk FA, Baez J, et al. Conference contribution Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience (2021) Enssle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Conference contribution Allogeneic Hematopoietic Cell Transplantation in Patients <= 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial- (2021) Bornhaeuser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, Platzbecker U, et al. Conference contribution Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning (2021) Eckardt JN, Rollig C, Kramer M, Stasik S, Georgi JA, Heisig P, Kroschinsky FP, et al. Conference contribution Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute BLymphoblastic Leukemia (INITIAL-1 trial) (2021) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial (2021) Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duhrsen U, Hahn D, Meidenbauer N, et al. Conference contribution